We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CNA Financial (CNA) Q2 Earnings Coming Up: What's in Store?
Read MoreHide Full Article
CNA Financial (CNA - Free Report) is slated to report second-quarter 2019 results on Aug 5, before market open. The company delivered positive surprise in three of the last four quarters.
Let’s see how things are shaping up for this announcement.
Premiums are likely to be supported by increase in new business, renewal premium change and solid retention. The Zacks Consensus Estimate for the metric is pegged at $1.8 billion, implying an increase of 1.2% from the year-ago period.
International premiums are likely to be low, given re-underwriting and reinsurance actions taken to revive the underperforming operations within international.
Improved interest rates, higher limited partnership returns and stable fixed income returns are likely to aid net investment income in the to-be reported quarter. The Zacks Consensus Estimate for investment income is pegged at $502 million.
Revenues are likely to benefit from improved premiums and higher investment income.
A benign catastrophe environment is likely to aid underwriting profitability. Combined ratio is estimated at 94%.
CNA Financial continues to efficiently manage its long-term care book of business through product claim management, thereby mitigating risk and aiding rate increase.
The Life & Group segment is expected to benefit from solid persistency.
Expenses are likely to increase on higher net claims and benefits plus amortization of deferred acquisition costs. This rise in expenses could restrict operating margin expansion.
The Zacks Consensus Estimate for earnings stands at $1.01, implying nearly 2% increase from the year-earlier quarter figure.
What Our Quantitative Model States
Our proven model does not conclusively show that CNA Financial is likely to beat on earnings this time around. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: CNA Financial has an Earnings ESP of 0.00%. This is because the Most Accurate Estimate as well as the Zacks Consensus Estimate is pegged at $1.01. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: CNA Financial carries a Zacks Rank #4 (Sell)
We caution against Zacks Rank 4 or 5 (Strong Sell) stocks going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Some stocks from the insurance industry with the perfect mix of elements to outshine estimates in their upcoming release are as follows:
American Financial Group (AFG - Free Report) has an Earnings ESP of +0.66% and a Zacks Rank of 3. The company is scheduled to release second-quarter earnings on Aug 6.
American International Group (AIG - Free Report) has an Earnings ESP of +0.09% and a Zacks Rank of 2. The company is slated to announce second-quarter earnings on Aug 7.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
CNA Financial (CNA) Q2 Earnings Coming Up: What's in Store?
CNA Financial (CNA - Free Report) is slated to report second-quarter 2019 results on Aug 5, before market open. The company delivered positive surprise in three of the last four quarters.
Let’s see how things are shaping up for this announcement.
Premiums are likely to be supported by increase in new business, renewal premium change and solid retention. The Zacks Consensus Estimate for the metric is pegged at $1.8 billion, implying an increase of 1.2% from the year-ago period.
International premiums are likely to be low, given re-underwriting and reinsurance actions taken to revive the underperforming operations within international.
Improved interest rates, higher limited partnership returns and stable fixed income returns are likely to aid net investment income in the to-be reported quarter. The Zacks Consensus Estimate for investment income is pegged at $502 million.
Revenues are likely to benefit from improved premiums and higher investment income.
A benign catastrophe environment is likely to aid underwriting profitability. Combined ratio is estimated at 94%.
CNA Financial continues to efficiently manage its long-term care book of business through product claim management, thereby mitigating risk and aiding rate increase.
The Life & Group segment is expected to benefit from solid persistency.
Expenses are likely to increase on higher net claims and benefits plus amortization of deferred acquisition costs. This rise in expenses could restrict operating margin expansion.
The Zacks Consensus Estimate for earnings stands at $1.01, implying nearly 2% increase from the year-earlier quarter figure.
What Our Quantitative Model States
Our proven model does not conclusively show that CNA Financial is likely to beat on earnings this time around. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: CNA Financial has an Earnings ESP of 0.00%. This is because the Most Accurate Estimate as well as the Zacks Consensus Estimate is pegged at $1.01. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
CNA Financial Corporation Price and EPS Surprise
CNA Financial Corporation price-eps-surprise | CNA Financial Corporation Quote
Zacks Rank: CNA Financial carries a Zacks Rank #4 (Sell)
We caution against Zacks Rank 4 or 5 (Strong Sell) stocks going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Some stocks from the insurance industry with the perfect mix of elements to outshine estimates in their upcoming release are as follows:
Voya Financial (VOYA - Free Report) is set to report second-quarter earnings on Aug 6. The company has an Earnings ESP of +1.42% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
American Financial Group (AFG - Free Report) has an Earnings ESP of +0.66% and a Zacks Rank of 3. The company is scheduled to release second-quarter earnings on Aug 6.
American International Group (AIG - Free Report) has an Earnings ESP of +0.09% and a Zacks Rank of 2. The company is slated to announce second-quarter earnings on Aug 7.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>